BioSante Pharmaceuticals says that its planned merger with Cell Genesys will bring in between $20 million and $25 million, which can fund its development program for a gel to treat female sexual dysfunction. LibiGel is now in Phase III trials and the company expects to file for an approval in early 2011. "We would hope to close the merger somewhere between September 30 and October 30, and that will bring in between $20 and $25 million into BioSante, which will allow us to continue the program we have ongoing right now," CEO Stephen Simes told Bloomberg. Release | Report